Compare ALG & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALG | MESO |
|---|---|---|
| Founded | 1955 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 108 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 1996 | 2005 |
| Metric | ALG | MESO |
|---|---|---|
| Price | $167.95 | $15.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $225.00 | N/A |
| AVG Volume (30 Days) | 137.1K | ★ 177.2K |
| Earning Date | 05-04-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.96 | N/A |
| Revenue | ★ $1,603,715,000.00 | N/A |
| Revenue This Year | $5.26 | $629.74 |
| Revenue Next Year | $3.97 | $30.65 |
| P/E Ratio | $34.60 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $145.76 | $13.05 |
| 52 Week High | $219.88 | $21.50 |
| Indicator | ALG | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 52.03 | 42.83 |
| Support Level | $167.49 | $15.37 |
| Resistance Level | $172.00 | $16.06 |
| Average True Range (ATR) | 4.96 | 0.42 |
| MACD | 0.54 | -0.22 |
| Stochastic Oscillator | 50.38 | 1.74 |
Alamo Group Inc is engaged in the design, manufacture, and servicing of high-quality vegetation management and infrastructure maintenance equipment for governmental, industrial, and agricultural use. Its products include agricultural implements, tree and branch chippers, forestry/wood recycling equipment, street and parking lot sweepers, leaf and debris collection equipment, truck-mounted highway attenuator trucks, vacuum trucks, hydro-excavation equipment, telescopic boom excavators, snow removal equipment, etc. The company's reportable segments are Vegetation Management, which generates the maximum revenue, and Industrial Equipment. Geographically, the company generates maximum revenue from the United States, followed by Canada, France, the UK, Brazil, the Netherlands, and other regions.
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.